top of page

PARSIFAL

STUDY TO EVALUATE THE EFFICACY AND SAFETY OF PALBOCICLIB IN COMBINATION WITH FULVESTRANT OR LETROZOLE IN PATIENTS WITH ER+, HER2- LOCALLY ADVANCED OR METASTATIC BREAST CANCER.

CLINICAL TRIAL DETAILS

A RANDOMIZED, MULTICENTER, OPEN-LABEL, PHASE II TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF PALBOCICLIB IN COMBINATION WITH FULVESTRANT OR LETROZOLE IN PATIENTS WITH HER2 NEGATIVE, ER+ METASTATIC BREAST CANCER.

THIS IS AN INTERNATIONAL, RANDOMIZED, OPEN-LABEL, CONTROLLED, MULTICENTER PHASE II CLINICAL TRIAL TO INVESTIGATE AND COMPARE THE SAFETY AND EFFICACY OF PALBOCICLIB COMBINED WITH FULVESTRANT OR LETROZOLE IN WOMEN WITH ER+, HER2- LOCALLY ADVANCED OR METASTATIC BREAST CANCER.

COUNTRY

STATUS

TUMOR TYPE

PHASE

N

SITES

HR+ HER2neg ABC

50

486

II

Spain, France, Italy, UK, Germany, Russia, Czech Republic

Closing

PRESS RELEASE

home_fondo_you_barra.jpg

SCIENTIFIC IMPACT

home_fondo_you_barra.jpg

BLOG ARTICLES RELATED

home_fondo_you_barra.jpg

TRIAL SITES

home_fondo_you_barra.jpg
Hospital Universitari Vall D'Hebron (Spain) Instituto Valenciano de Oncología (IVO) (Spain) Hospital Universitario Reina Sofía (Spain) Institut Català d' Oncologia L'Hospitalet (ICO) (Spain) Hospital del Mar (Spain) Hospital Universitario Central de Asturias (HUCA) (Spain) Hospital Universitario Virgen del Rocío (Spain) Institut Català d' Oncologia Girona (ICO) (Spain) Hospital Universitari Sant Joan de Reus (Spain) Hospital Universitario Juan Ramón Jiménez (Spain) Complejo Hospitalario de Navarra (Spain) Hospital San Pedro de Alcántara (Spain) Hospital Universitario de Basurto (Spain) Hospital Clínico Universitario Lozano Blesa (Spain) Hospital Universitario Miguel Servet (Spain) Complejo Hospitalario Universitario de Santiago (CHUS) (Spain) Hospital Universitario La Paz (Spain) Hospital Provincial de Castellón (Spain) Instituto Oncológico Baselga - Hospital Quiron Salud Barcelona (Spain) Hospital Arnau de Vilanova de Valencia (Spain) Hôpital Tenon AP-HP (France) Institut Universitaire du Cancer Toulouse, Toulouse (France) Institut Curie (France) Centre Paul Strauss (France) Hopital Europeen Georges Pompidou (France) Fondazione IRCCS Istituto Nazionale dei Tumori (Italy) Instituto Europeo di Oncologia (Italy) AOU policlinico di Modena (Italy) Ospedale San Gerardo (Italy) Ospedale Antonio Perrino (Italy) Istituti Ospitalieri Cremona (Italy) Ospedale Guglielmo da Saliceto (Italy) Azienda Ospedaliero-Universitaria Cittá de la Salute e della Scienza (Italy) Azienda Ospedaliero- Universitaria di Cagliari (Italy) Barts Cancer Institute (UK) Royal United Hospitals Bath NHS Foundation Trust (UK) Nottingham University Hospitals NHS Trust (UK) Abertawe Bro Morgannwg University Local Health Board, Singleton Hospital (UK) Queens Hospital, Barking, Havering and Redbridge University Hospitals NHS Trust (UK) Royal Cornwall Hospital NHS Trust (UK) The Christie NHS Foundation Trust (UK) National Center for Tumor Disease (NCT) (Germany) Medizinisches Versorgungszentrum des Städtischen Klinikums Dessau (MVZ) - Frauenheilkunde (Germany) General University Hospital in Prague (Czech Republic) Onkologická klinika Fakultní nemocnice Olomouc (Czech Republic) Regional Clinical Oncology Hospital (Russia) Moscow Clinical Scientific Center of the Moscow Health Department (Russia) Republican Clinical Oncological Dispesary of Tatarstan Ministry of Health (Russia) St. Petersburg Clinical Research and Practical Center of Specialized Types of Medical Care (Russia) Oncologic Dispensary of Pyatigorsk (Russia)
bottom of page